

Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes.

World Journal of Urology

Wojciech Krajewski¹, Marco Moschini², Joanna Chorbińska¹, Łukasz Nowak¹, Sławomir Poletajew³, Andrzej Tukiendorf⁴, Luca Afferi², Jeremy Yuen-Chun Teoh⁵, Tim Muilwijk⁶, Steven Joniau⁶, Alessandro Tafuri⁷, Alessandro Antonelli⁷, Francesco Cianflone⁷, Andrea Mari⁸, Ettore Di Trapani⁹, Kees Hendricksen¹⁰, Mario Alvarez-Maestro¹¹, Andrea Rodríguez Serrano¹¹, Giuseppe Simone¹², Stefania Zamboni¹³, Claudio Simeone¹³, Maria Cristina Marconi¹³, Riccardo Mastroianni¹², Guillaume Ploussard¹⁴, Ekaterina Laukhtina^{15,16}, Karl Tully¹⁷, Anna Kołodziej¹, Joanna Krajewska¹⁸, Radosław Piszczek¹⁹, Evangelos Xylinas²⁰, Romuald Zdrojowy¹,


1. Department of Urology and Oncologic Urology, Wrocław Medical University, Wrocław, Poland
2. Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland
3. Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland
4. Department of Public Health, Wrocław Medical University, Wrocław, Poland
5. S.H.Ho Urology, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China
6. Department of Urology, University Hospitals Leuven, Leuven, Belgium.
7. Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
8. Department of Urology, Careggi Hospital, University of Florence, Florence, Italy
9. Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy
10. Department of Urology, Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands
11. Department of Urology Hospital Universitario La Paz Madrid Spain
12. Oncologic Urology "Regina Elena" National Cancer Institute Department of Urology Via Elio Chianesi 53, 00144, Rome, Italy
13. Urology Unit, ASST Spedali Civili, Brescia, Italy; Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Italy

14. Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France
15. Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
16. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
17. Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany
18. Department and Clinic of Otolaryngology, Head and Neck Surgery, Wrocław Medical University
19. Department of Urology and Oncologic Urology, Lower Silesian Specialistic Hospital, Wrocław, Poland
20. Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris, France.

On behalf of European Association of Urology- Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group

Corresponding author: Wojciech Krajewski, MD PhD; Department of Urology and Oncological Urology, Wrocław Medical University, Wrocław, Poland Tel/fax: 0048717331010, Email: wk@softstar.pl, ORCID:

<https://orcid.org/0000-0003-1727-2283>



Online Resource 1 a. Recurrence-free survival for patients with negative reTURB ($p=0.007$). b. Progression-free survival for patients with negative reTURB ($p=0.005$). c. Recurrence-free survival for patients with positive reTURB ($p=0.931$). d. Progression-free survival for patients with positive reTURB ($p=0.991$)